

Health and Wellbeing Board



Date of meeting:	03 October 2025
Title of Report:	Plymouth Drugs Strategic Partnership Annual Report
Lead Member:	Councillor Mary Aspinall (Cabinet Member for Health and Adult Social Care)
Lead Strategic Director:	Professor Steve Maddern (Director of Public Health)
Author:	Kamal Patel
Contact Email:	Kamal.Patel@Plymouth.gov.uk
Your Reference:	N/A
Key Decision:	No
Confidentiality:	Part I - Official

Purpose of Report

To provide an annual progress update for the Plymouth Drugs Strategic Partnership for the year from 01 April 2024 to 31 March 2025.

Recommendations and Reasons

1. To endorse the action taken by the partnership in 2024-25
2. To provide comments on suggested areas of focus for the partnership going forward

Alternative options considered and rejected

1. To not endorse the action taken by the partnership.

Relevance to the Corporate Plan and/or the Plymouth Plan

Contributes to the following aspects of the corporate plan:

- Working with the NHS to provide better access to health, care and dentistry
- Providing quality public health services
- Focusing on prevention and early intervention

Contributes to following aspects of the Plymouth Plan:

- HEA1: Addressing health inequalities, improving health literacy
- HEA2: Delivering the best outcomes for children, young people and families
- HEA8: Delivering accessible health services and clinical excellence

Implications for the Medium Term Financial Plan and Resource Implications:

No impact

Financial Risks

None

Legal Implications

No legal implications identified by offer (Kamal Patel)

Carbon Footprint (Environmental) Implications:

None

Other Implications: e.g. Health and Safety, Risk Management, Child Poverty:

** When considering these proposals members have a responsibility to ensure they give due regard to the Council's duty to promote equality of opportunity, eliminate unlawful discrimination and promote good relations between people who share protected characteristics under the Equalities Act and those who do not.*

None

Appendices

**Add rows as required to box below*

Ref.	Title of Appendix	Exemption Paragraph Number (if applicable) <i>If some/all of the information is confidential, you must indicate why it is not for publication by virtue of Part 1 of Schedule 12A of the Local Government Act 1972 by ticking the relevant box.</i>						
		1	2	3	4	5	6	7
A	Plymouth Drugs Strategic Partnership Annual report 2024-25							

Background papers:

**Add rows as required to box below*

Please list all unpublished, background papers relevant to the decision in the table below. Background papers are unpublished works, relied on to a material extent in preparing the report, which disclose facts or matters on which the report or an important part of the work is based.

Title of any background paper(s)	Exemption Paragraph Number (if applicable) <i>If some/all of the information is confidential, you must indicate why it is not for publication by virtue of Part 1 of Schedule 12A of the Local Government Act 1972 by ticking the relevant box.</i>						
	1	2	3	4	5	6	7

Sign off:

Fin	N/A	Leg	N/A	Mon Off	N/A	HR	N/A	Assets	N/A	Strat Proc	N/A
Originating Senior Leadership Team member: Kamal Patel											
Please confirm the Strategic Director(s) has agreed the report? Yes											
Date agreed: 22/09/2025											
Cabinet Member approval: Councillor Mary Aspinall (Cabinet Member for Health and Adult Social Care) Approved by email.											
Date approved: 23/09/2025											

